Dexela CEO Ed Bullard Presents at UCL's Technology Innovation Forum - The Future of Imaging

Dexela’s Chief Executive Ed Bullard has been invited to give a presentation about Digital Breast Tomosynthesis at University College London’s first Technology Innovation Forum. UCL Advances has planned a series of events that bring together business leaders, investors and academic researchers to focus on the challenges of linking science-led innovation to emerging markets. The first of these will focus on ‘The Future of Imaging’ and will be held on Tuesday 16th October. The half-day Forum will be comprised of formal talks, informal networking and discussions, showcases and technical demonstrations. This event is being run in partnership with the Institute of Technology at London Business School. The National Endowment for Science, Technology, and the Arts (NESTA) is a sponsor of the event.

The ‘Future of Imaging’ is intended to show how recent advances in imaging technologies offer the prospect of radical new insights to a diverse range of problems including:

• New medical diagnostic tools for disease detection and surgical intervention
• Tools for biometric analyses and characterisation
• Increased security through the monitoring of human activities and behaviours
• Computer technologies for novel virtual and augmented realities

Ed Bullard will give a talk about Digital Breast Tomosynthesis, a novel 3D X-ray imaging modality, and about how Dexela is bringing innovative Digital Breast Tomosynthesis products to market.


For more information about the UCL Advances Technology Innovation Forum contact:

Timothy Barnes
Executive Director
UCL Advances
Tel: +44 (0) 7903 188 447
Fax: +44 (0) 7092 309 045
DD: +44 (0) 20 7679 7752
Email: t.barnes@ucl.ac.uk
Web: www.ucl.ac.uk/advances

For more information about Dexela Ltd please visit www.dexelaimaging.com or contact:

Edward Bullard
CEO Dexela Limited
Tel: +44 (0) 7980 210 710
Email: edward@dexelaimaging.com
Web: www.dexelaimaging.com

Notes to Editors

About Dexela
Formed in 2005 to address significant unmet medical need in the early detection of breast cancer, Dexela is developing innovative, low-radiation breast screening techniques that not only may extend the benefits of breast cancer screening to women under fifty, but may also reduce call backs due to false positive results and increase the sensitivity of breast cancer detection, leading to fewer cancers being missed by doctors.

Dexela has a talented and experienced team of award-winning scientists, as well as a strong portfolio of intellectual property and it is this team which has developed world-leading technology for the acquisition, processing and visualisation of high resolution 3-D images of the breast, a type of imaging known as Tomosynthesis. Dexela’s novel approach to Tomosynthesis has significant clinical advantages over competing approaches. They now intend to use this position to secure the leading role in the field and establish collaborative agreements with medical device manufacturers.


About UCL Advances
UCL Advances stimulates collaboration among researchers, business and investors driving innovations that benefit society and the economy.
www.ucl.ac.uk/advances/